Overview
XGN market data
Price History
XGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.93 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.05 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.59 – $12.23 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $105.8 · P/B 7.78 · P/S 1.55.
Company News
Exagen Announces Publication Of New Systematic Review Demonstrating That AVISE Lupus Algorithm Delivers Superior Diagnostic Accuracy And Consistency Across Patient Populations Compared With Conventional Serologic Tests AloneBenzinga · Jun 1, 2026, 1:03 PM
Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M EstBenzinga · May 11, 2026, 12:03 PM
8-K filing — EXAGEN INC. (XGN)SEC EDGAR · May 11, 2026, 12:03 PM
Exagen Q1 EPS $(0.17) Beats $(0.23) Estimate, Sales $17.306M Beat $16.414M EstimateBenzinga · May 11, 2026, 12:03 PM
Earnings Scheduled For May 11, 2026Benzinga · May 11, 2026, 11:11 AM